Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79874 | 0.80 | MAPK1 (0.37) | ALDH1A1 | |
| SCHEMBL6886114 | 0.76 | HCAR2 (0.37) | TDP1ALDH1A1NPSR1ATM | |
| Hydroxyamine SCHEMBL9901947 | 0.75 | ALDH1A1 (0.35) | TDP1ALDH1A1TSHR | |
| SCHEMBL26002442 | 0.75 | TDP1 (0.41) | TDP1ALDH1A1TSHRCA2NPSR1 | |
| SCHEMBL23621461 | 0.75 | TDP1 (0.41) | TDP1ALDH1A1TSHRCA2NPSR1 | |
| SCHEMBL31318429 | 0.72 | MAPK1 (0.34) | ALDH1A1 | |
| SCHEMBL7191344 | 0.72 | TDP1 (0.32) | TDP1 | |
| SCHEMBL15888456 | 0.72 | MAPK1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL9199136 | 0.72 | TDP1 (0.39) | TDP1ALDH1A1TSHRCA2NPSR1 | |
| SCHEMBL4264209 | 0.72 | TDP1 (0.39) | TDP1ALDH1A1TSHRCA2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222426-A1 | Anti-Bacterial Agents | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2010-09-02 | — | — | US | disclosed |
| US-5852027-A | Antiviral 1,3-dioxolane nucleoside analogues | EMORY UNIVERSITY (US) | 1998-12-22 | — | — | US | disclosed |
| US-5276151-A | Reacting a 2-O-protected-5-O-acylated-1,3-dioxolane with oxygen or nitrogen protected purine or pyrimidine base; titanium catalyst | EMORY UNIVERSITY (US) | 1994-01-04 | — | — | US | disclosed |
| WO-1992014729-A1 | ANTIVIRAL 1,3-DIOXOLANE NUCLEOSIDES AND SYNTHESIS THEREOF | EMORY UNIVERSITY (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222426-A1 | Anti-Bacterial Agents | B3GNT2, LSS, GNE | TDP1 4708/4885ALDH1A1 3786/4885TSHR 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.